NasdaqCM - Delayed Quote USD

Zura Bio Limited (ZURA)

3.4800 +0.1700 (+5.14%)
At close: April 23 at 4:00 PM EDT
3.4000 -0.08 (-2.30%)
After hours: April 23 at 4:27 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Verender S. Badial Chief Financial Officer 374.92k -- 1973
Dr. Michael D. Howell Ph.D. Chief Scientific Officer & Head of Translational Medicine 1.97M -- 1977
Ms. Kimberly Ann Davis Chief Legal Officer & Secretary 2.16M -- 1968
Mr. Robert Lisicki President, CEO & Director -- -- 1968
Dr. Gary Whale Ph.D. Chief Technology Officer -- -- 1974
Ms. Theresa Lowry Chief Human Resources Officer -- -- 1974
Mr. David Brady Head of Business Development 125.05k -- --
Dr. Kiran Nistala MBBS, Ph.D. Chief Medical Officer & Head of Development -- -- 1973

Zura Bio Limited

1489 W. Warm Springs Road
Suite 110
Henderson, NV 89014
United States
702-757-6133 https://zurabio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
14

Description

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

Corporate Governance

Zura Bio Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers

BNTC Benitec Biopharma Inc.
6.86
+2.08%
 
CGEM Cullinan Therapeutics, Inc.
16.67
+6.65%
 
TRML Tourmaline Bio, Inc.
15.09
-2.65%
 
ABVC ABVC BioPharma, Inc.
1.3500
+29.81%
 
TSBX Turnstone Biologics Corp.
3.0600
+4.79%
 
ACXP Acurx Pharmaceuticals, Inc.
2.0400
+3.03%
 
RANI Rani Therapeutics Holdings, Inc.
6.69
+0.30%
 
BRTX BioRestorative Therapies, Inc.
1.3400
-2.19%
 
CTNM Contineum Therapeutics, Inc.
15.91
+1.08%
 
TCRX TScan Therapeutics, Inc.
7.26
+1.97%